216 related articles for article (PubMed ID: 17647293)
1. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression.
Yoo BC; Kim JH; Kim TH; Koh KC; Um SH; Kim YS; Lee KS; Han BH; Chon CY; Han JY; Ryu SH; Kim HC; Byun KS; Hwang SG; Kim BI; Cho M; Yoo K; Lee HJ; Hwang JS; Kim YS; Lee YS; Choi SK; Lee YJ; Yang JM; Park JW; Lee MS; Kim DG; Chung YH; Cho SH; Choi JY; Kweon YO; Lee HY; Jeong SH; Yoo HW; Lee HS
Hepatology; 2007 Oct; 46(4):1041-8. PubMed ID: 17647293
[TBL] [Abstract][Full Text] [Related]
2. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B.
Yoo BC; Kim JH; Chung YH; Lee KS; Paik SW; Ryu SH; Han BH; Han JY; Byun KS; Cho M; Lee HJ; Kim TH; Cho SH; Park JW; Um SH; Hwang SG; Kim YS; Lee YJ; Chon CY; Kim BI; Lee YS; Yang JM; Kim HC; Hwang JS; Choi SK; Kweon YO; Jeong SH; Lee MS; Choi JY; Kim DG; Kim YS; Lee HY; Yoo K; Yoo HW; Lee HS
Hepatology; 2007 May; 45(5):1172-8. PubMed ID: 17464992
[TBL] [Abstract][Full Text] [Related]
3. Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy.
Lee KS; Byun KS; Chung YH; Paik SW; Han JY; Yoo K; Yoo HW; Yoo BC; Lee HS
Intervirology; 2007; 50(4):296-302. PubMed ID: 17622789
[TBL] [Abstract][Full Text] [Related]
4. Comparison between clevudine and entecavir treatment for antiviral-naïve patients with chronic hepatitis B.
Kim HJ; Park DI; Park JH; Cho YK; Sohn CI; Jeon WK; Kim BI
Liver Int; 2010 Jul; 30(6):834-40. PubMed ID: 20408946
[TBL] [Abstract][Full Text] [Related]
5. [Treatment efficacy of clevudine, entecavir and lamivudine in treatment-naive patients with HBeAg-positive chronic hepatitis B].
Bae SH; Baek YH; Lee SW; Han SY
Korean J Gastroenterol; 2010 Dec; 56(6):365-72. PubMed ID: 21173560
[TBL] [Abstract][Full Text] [Related]
6. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B.
Marcellin P; Mommeja-Marin H; Sacks SL; Lau GK; Sereni D; Bronowicki JP; Conway B; Trepo C; Blum MR; Yoo BC; Mondou E; Sorbel J; Snow A; Rousseau F; Lee HS
Hepatology; 2004 Jul; 40(1):140-8. PubMed ID: 15239097
[TBL] [Abstract][Full Text] [Related]
7. A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B.
Lee HS; Chung YH; Lee K; Byun KS; Paik SW; Han JY; Yoo K; Yoo HW; Lee JH; Yoo BC
Hepatology; 2006 May; 43(5):982-8. PubMed ID: 16628625
[TBL] [Abstract][Full Text] [Related]
8. Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study.
Lau GK; Leung N
Korean J Hepatol; 2010 Sep; 16(3):315-20. PubMed ID: 20924215
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of 48-week clevudine therapy for chronic hepatitis B].
Kim MH; Kim KA; Lee JS; Lee HW; Kim HJ; Yun SG; Kim NH; Bae WK; Moon YS
Korean J Hepatol; 2009 Sep; 15(3):331-7. PubMed ID: 19783882
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of entecavir switching therapy in chronic hepatitis B patients with clevudine-induced myopathy].
Lee JW; Lee YJ; Lee JJ; Kim JH; Jung YK; Kwon OS; Choi DJ; Kim YS; Kim JH
Korean J Gastroenterol; 2013 Jan; 61(1):30-6. PubMed ID: 23354347
[TBL] [Abstract][Full Text] [Related]
11. Clinical and virological responses to clevudine therapy in chronic hepatitis B patients: results at 1 year of an open-labelled prospective study.
Ko SY; Kwon SY; Choe WH; Kim BK; Kim KH; Lee CH
Antivir Ther; 2009; 14(4):585-90. PubMed ID: 19578244
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B.
Kim SB; Song IH; Kim YM; Noh R; Kang HY; Lee HIe; Yang HY; Kim AN; Chae HB; Lee SH; Kim HS; Lee TH; Kang YW; Lee ES; Kim SH; Lee BS; Lee HY
World J Gastroenterol; 2012 Dec; 18(47):6943-50. PubMed ID: 23322992
[TBL] [Abstract][Full Text] [Related]
13. Clevudine demonstrates potent antiviral activity in naïve chronic hepatitis B patients.
Lee JS; Park ET; Kang SS; Gu ES; Kim JS; Jang DS; Lee KS; Lee JS; Park NH; Bae CH; Baik SK; Yu BJ; Lee SH; Lee EJ; Park SI; Bae M; Shin JW; Choi JH; Gu C; Moon SK; Chun GJ; Kim JH; Kim HS; Choi SK
Intervirology; 2010; 53(2):83-6. PubMed ID: 19955812
[TBL] [Abstract][Full Text] [Related]
14. Clevudine-induced viral response, associated with continued reduction of HBsAg titer, was durable after the withdrawal of therapy.
Lee HS; Yoo BC; Lee KS; Kim JH; Um SH; Ryu SH; Lee YS; Kim YS; Yoo K; Han JY; Hwang JS; Kim TH; Yang JM; Lee HJ; Chon CY; Cho M; Han BH; Hwang SG; Byun KS; Chung YH; Cho SH; Koh KC; Kim BI; Kim HC; Paik SW; Lee MS; Yoo HW; Han CJ
J Gastroenterol; 2011 Mar; 46(3):410-4. PubMed ID: 21181212
[TBL] [Abstract][Full Text] [Related]
15. [Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients].
Ling N; Zhou Z; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):346-9. PubMed ID: 17524266
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B.
Lim SG; Krastev Z; Ng TM; Mechkov G; Kotzev IA; Chan S; Mondou E; Snow A; Sorbel J; Rousseau F
Antimicrob Agents Chemother; 2006 May; 50(5):1642-8. PubMed ID: 16641430
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of initial treatment with clevudine in naive patients with chronic hepatitis B.
Yang HW; Lee BS; Lee TH; Lee HY; Nam KW; Kang YW; Chae HB; Kim SH; Kim SB; Lee HIe; Kim AN; Song IH; Lee SH; Kim HS
Korean J Intern Med; 2010 Dec; 25(4):372-6. PubMed ID: 21179274
[TBL] [Abstract][Full Text] [Related]
18. [Long-term clevudine therapy in nucleos(t)ide-naïve and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases].
Lee HJ; Eun JR; Lee CH; Hwang JS; Suh JI; Kim BS; Jang BK
Korean J Hepatol; 2009 Jun; 15(2):179-92. PubMed ID: 19581770
[TBL] [Abstract][Full Text] [Related]
19. Treatment outcomes of clevudine versus lamivudine at week 48 in naïve patients with HBeAg positive chronic hepatitis B.
Kim IH; Lee S; Kim SH; Kim SW; Lee SO; Lee ST; Kim DG; Choi CS; Kim HC
J Korean Med Sci; 2010 May; 25(5):738-45. PubMed ID: 20436711
[TBL] [Abstract][Full Text] [Related]
20. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
